Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Has Average Target Price of $17.29 According to Analysts

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has earned an average recommendation of “Reduce” from the eight brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $16.71.

IART has been the subject of a number of recent research reports. Wall Street Zen downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. BMO Capital Markets dropped their price objective on Integra LifeSciences from $18.00 to $15.00 and set a “market perform” rating for the company in a report on Monday, October 5th. Weiss Ratings cut shares of Integra LifeSciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd. UBS Group initiated coverage on shares of Integra LifeSciences in a report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 target price on the stock. Finally, Citigroup restated a “neutral” rating and set a $15.00 price objective (down from $19.00) on shares of Integra LifeSciences in a research note on Monday, October 5th.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $13.45 on Tuesday. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. The company has a market capitalization of $1.05 billion, a P/E ratio of -149.43, a price-to-earnings-growth ratio of 0.70 and a beta of 1.21. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $20.49. The company’s 50-day moving average is $15.75 and its 200 day moving average is $15.52.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.48 by $0.08. The business had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities research analysts forecast that Integra LifeSciences will post 2.39 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Sequoia Financial Advisors LLC grew its stake in Integra LifeSciences by 27.4% during the 1st quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after buying an additional 3,059 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Integra LifeSciences in the second quarter valued at $82,000. Integrated Wealth Concepts LLC bought a new stake in Integra LifeSciences in the second quarter valued at $84,000. State of Wyoming lifted its stake in Integra LifeSciences by 26.4% in the first quarter. State of Wyoming now owns 25,276 shares of the life sciences company’s stock valued at $238,000 after buying an additional 5,278 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Integra LifeSciences by 80.8% during the first quarter. Amundi now owns 19,430 shares of the life sciences company’s stock valued at $183,000 after acquiring an additional 8,681 shares during the period. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.